[1] 张航, 张婷. 肝动脉化疗栓塞联合血管内皮抑素治疗肝癌疗效的短期随访. 肝脏, 2018, 23:906-908.
[2] 徐文杰, 曹刚, 张根山,等. 聚乙烯醇栓塞微球可载药微球介入治疗中晚期肝癌的临床疗效及安全性观察. 实用癌症杂志, 2017, 32:1999-2001.
[3] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 临床肝胆病杂志, 2011, 20:929-946.
[4] Dueck AC, Mitchell SA, Mendoza TR, et al. Responsiveness of items from the patient-reported outcomes version of the common terminology criteria for adverse events. Qual Life Res, 2014, 23:37-38.
[5] 赵倩, 颜志平. 载药微球经导管动脉化疗栓塞治疗肝癌研究进展. 介入放射学杂志, 2017, 26:1052-1056.
[6] 周永祥, 张景俊, 罗志刚, 等. CalliSpheres○R载药微球栓塞治疗高龄肝癌患者的安全性分析. 广东医学, 2018, 39:1561-1565.
[7] Wu B, Zhou J, Ling G, et al. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. World J Surg Oncol, 2018, 16:69-76.
[8] Zhou G, Zhang Y, Zhou T, et al. Abstract No. 507 Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres○R beads in Chinese hepatocellular carcinoma patients. J Vasc Interv Radiol, 2018, 29:S213-S214.
[9] Zhang S, Huang C, Li Z, et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers.. Drug Deliv, 2017, 24:1011-1017. |
